Open AccessA direct comparison of selective BH3-mimetics reveals BCL-XL, BCL-2 and MCL-1 as promising therapeutic targets in neuroblastoma
Author(s) -
Annika Bierbrauer,
Maureen Jacob,
Meike Vogler,
Simone Fulda
Publication year - 2020
Publication title -
british journal of cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.833
H-Index - 236
eISSN - 1532-1827
pISSN - 0007-0920
DOI - 10.1038/s41416-020-0795-9
Subject(s) - neuroblastoma , bcl xl , apoptosis , cancer research , programmed cell death , cell culture , blot , bcl 2 family , biology , chemistry , biochemistry , genetics , gene
Despite advances in the treatment of neuroblastoma, patients with high-risk disease still have dismal survival prognosis. Neuroblastoma cells display elevated expression of the antiapoptotic BCL-2 proteins, suggesting that BH3-mimetics may be a promising treatment option. Here, we investigated the role of BCL-2, BCL-X L and MCL-1 in neuroblastoma.